meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
chemotherapy
antifolates
pralatrexate
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus BSC
gene alteration target therapy
BRAF gene alteration targeted therapy
BRAF inhibitor
combined BRAF-MEK inhibitors
trametinib plus dabrafenib
EGFR gene alteration
osimertinib
KRAS gene alteration targeted therapy
sotorasib
MET gene alteration targeted therapy
capmatinib
HER inhibitor
EGFR inhibitor
afatinib based treatment
afatinib alone
afatinib plus BSC
afatinib plus paclitaxel
dacomitinib
erlotinib based treatment
erlotinib alone
erlotinib plus gemcitabine
erlotinib plus pemetrexed
tivantinib plus erlotinib
gefitinib based treatment
gefitinib alone
gefitinib plus BSC
gefitinib plus SoC (rechallenge)
icotinib
nimotuzumab based treatment
nimotuzumab plus gefitinib
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
durvalumab plus osimertinib
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab (10mg/kg)
pembrolizumab (2mg/kg)
Tislelizumab
Immune checkpoint association
durvalumab plus tremelimumab
VEGF(R) inhibitor
sorafenib
vandetanib
no study with result for this clinical condition